Atara Biotherapeutics vs DBV Technologies
ATRA and DBVT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATRA and DBVT compare
DBV Technologies is the larger company, worth 44 times as much as Atara Biotherapeutics ($3.6B against $82.6M).
DBV Technologies grew revenue faster over the last twelve months (−31.6% versus −97.4% for Atara Biotherapeutics).
Atara Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of −369% compared with −5405% at DBV Technologies.
Atara Biotherapeutics scores higher on the StockData Score (7 against 6 for DBV Technologies), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATRA | DBVT |
|---|---|---|
| Size and price | ||
| Market cap | $82.6M | $3.6B |
| Share price | $8.23 | $11.51 |
| Change, 1 year | −33.1% | −17.6% |
| Change, 5 years | −98.2% | 88.1% |
| Beta (5Y) | 1.65 | 0.58 |
| Employees | 14 | 125 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 0 | 0 |
| Growth score | 1 (better) | 0 |
| Performance score | 1 (better) | 0 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 20.8× (better) | 943× |
| P/B | – | 24.4× |
| FCF yield | – | −5.3% |
| Growth | ||
| Revenue growth (TTM) | −97.4% | −31.6% (better) |
| Revenue growth, 5Y average | – | −13.0% |
| Net income growth (TTM) | −162% | – |
| Profitability | ||
| Operating margin | −344% (better) | −5432% |
| Net margin | −369% (better) | −5405% |
| FCF margin | – | −4998% |
| Return on equity | – | −206% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Current ratio | 1.72 | 3.24 (better) |
| Altman Z-score | −153.99 | 27.93 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −10.4% | – |
| Shareholder yield | −10.4% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 44.5% | 6.8% |
| Held by insiders | 55.5% | 12.1% |
| Insider net buying, 12 months | $2.0M (better) | −$15.5M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | 6.6% | – |
Go deeper
- ATRA stock overview
- ATRA income statement
- ATRA valuation and score
- DBVT stock overview
- DBVT income statement
- DBVT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.